HGH Fragment 176-191 vs Palmitoyl Tetrapeptide-7
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
HGH Fragment 176-191
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.
Full details →Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →Side-by-Side Comparison
| Aspect | HGH Fragment 176-191 | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Mechanism | Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors. | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. |
| Typical Dosage | Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio. | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. |
| Administration | Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection. | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. |
| Side Effects | Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly. | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. |
| Best For |